D3 Oncology Solutions Now Includes Via Oncology Pathways for Medical Oncology
PITTSBURGH, March 1, 2011 /PRNewswire/ — D3 Oncology Solutions (D3), formerly D3 Radiation Oncology Solutions, has added Via Oncology Pathways for medical oncology to the company’s suite of solutions. With this new offering, D3 now offers integrated pathways programs to both medical and radiation oncology practices across the globe. Via Oncology Pathways are evidence-based clinical algorithms that standardize best practice cancer treatment, optimize patient outcomes, minimize toxicities, and promote efficient resource utilization. These cancer care pathways have been developed and implemented across multiple practices by both academic and community based oncologists since 2005.
Currently, D3′s Via Oncology Pathways cover more than 85 percent of cancer diagnoses and include chemotherapy and biologics, radiation therapy, prognostic testing and supportive care treatments. All aspects of the pathways are delivered through a web-based, patient-specific, point of care decision-support tool that integrates into the practice’s other information technologies. Additionally, advance care planning support is seamlessly built into the software to support the physician’s workflow.
“Oncologists have asked us to help them become optimally positioned to participate in many of the healthcare reform vehicles such as medical homes, accountable care organizations (ACOs) and demonstration projects. They want to be able to prove the value of their cancer program to patients, referring physicians and health plans by clearly demonstrating evidence-based, cost-effective care,” said Kathleen Lokay, president, D3 Oncology Solutions. “D3′s Via Oncology Pathways are a proven tool for measuring and proving the value of care delivered.”
Every quarter, approximately 30 different disease-specific physician committees of academic and community-based physicians convene to review the Pathways based on their independent evaluation of the latest medical literature.
“It’s no longer enough to simply say that you have quality. The practices that will be successful in the future are those that can demonstrate a system of quality and cost effectiveness and quantify those results on a repeatable basis. Via Oncology Pathways provide the tools to prove it,” noted Peter Ellis, M.D., medical director for Via Oncology Pathways and a practicing medical oncologist at UPMC.
About D3 Oncology Solutions
The mission of D3 Oncology Solutions is to develop and deliver leading edge solutions that accelerate the quality, safety, efficiency and outcomes of cancer patients’ care at radiation and medical oncology centers around the world.
With unmatched expertise for more than a decade, D3 has assisted hundreds of cancer centers in the United States and internationally. D3′s solutions are guided by close collaboration with leading radiation oncologists, medial oncologists and medical physicists at UPMC and UPMC Cancer Centers.
From flexible options for linear accelerator commissioning, clinical training and radiation treatment planning to tools and programs that support clinical quality such as Via Oncology Pathways, D3′s suite of solutions accelerates excellence in the delivery of cancer care.
D3 is an affiliate of UPMC, an integrated global health enterprise headquartered in Pittsburgh and one of the leading health systems in t he United States. For more information, visit www.d3onc.com or call (412) 365-0710.
Media Contacts D3: Andrew Bailey (412) 365-0744 or firstname.lastname@example.org Euro RSCG Worldwide PR: Ellen Wein (412) 456-0986 or email@example.com
SOURCE D3 Oncology Solutions